Nanjing Regenecore Biotech Co., Ltd.
Clinical trials sponsored by Nanjing Regenecore Biotech Co., Ltd., explained in plain language.
-
New injection for blood cancers enters first human tests
Disease control Recruiting nowThis study tests a new drug called RJK-RT2831 for the first time in people with blood cancers. The main goal is to check its safety and find the best dose. About 71 adults aged 18 to 74 will take part. The drug is given as an injection.
Phase: PHASE1 • Sponsor: Nanjing RegeneCore Biotech Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New injection aims to cut COPD Flare-Ups in half
Disease control Recruiting nowThis study tests an experimental injection called RC1416 in 180 adults aged 40-85 with moderate to severe COPD. The goal is to see if it can reduce the number of serious flare-ups and improve lung function compared to a placebo. Participants will receive either the drug or a dumm…
Phase: PHASE2 • Sponsor: Nanjing RegeneCore Biotech Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:49 UTC